Pharma News, 2024

Amongst abstracts announced yesterday for the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting was positive data from a Phase II trial by Netherlands-based Merus.

Merck & Co (MSD) has announced positive data for its antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan from two studies that recruited patients with lung and breast cancer...

Otsuka Pharmaceutical has axed the development of its dementia drug, AVP-786, following a disappointing Phase III readout (NCT03393520).

Johnson & Johnson (J&J) has announced positive phase 3 results for Tremfya (guselkumab) in adult patients with moderately to severe active Crohn’s disease (CD).

Genmab has concluded the previously announced acquisition of clinical-stage biotechnology company ProfoundBio in a $1.8bn cash transaction.

The FDA has granted a Fast Track Designation to RAG-01, a first-in-class small activating RNA (saRNA) therapeutic under review for the treatment of patients with BCG-unresponsive non–muscle-...

According to the investigators, these findings support the investigation of rilzabrutinib in patients with asthma in a phase 3 trial program.

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditio...

LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have a lot of confidence ...

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted. The FDA approval for infigratini...

Glenmark Pharmaceuticals subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India. Tislelizumab and Zanubrutinib will be commer...

Zai Lab and Innoviva Specialty Therapeutics have announced the approval of China’s National Medical Products Administration (NMPA) for Zai’s new drug application (NDA) submitted fo...